Five Prime Therapeutics
Unicorn exit · $1.9Bacquired by AmgenSouth San Francisco, US · 2 known investors
Find your way into Five Prime Therapeutics
Acquired by Amgen March 2021 · $1.9B ($38.00 per share in cash, ~$1.9 billion equity value) · source ↗
Five Prime Therapeutics was a clinical-stage biotech in South San Francisco developing protein- and antibody-based immuno-oncology therapies, including the FGFR2b-targeting antibody bemarituzumab for gastric cancer.
Founders & leadership
LT
WM
W. Michael Kavanaugh, M.D.Executive
JH
Julie Hambleton, M.D.Executive
FW
Francis W. SarenaExecutive
AM
Aron M. KnickerbockerExecutive
ML
Marc L. BelskyExecutive
Board
BG
Brian G AtwoodBoard director
FE
Fred E. Cohen, M.D., D.Phil.Board director
MD
Mark D. McDadeBoard director
RL
R. Lee DouglasBoard director
FM
Franklin M. Berger, CFABoard director
PK
Peder K. Jensen, M.D.Board director
Investors · 2
Reported raises · per SEC filings
Form D private placements$21M disclosed across 1 round · 2014
▶$21MraisedMar 2014 · 1 investors · BiotechnologyRule 506(b)
▶$21MraisedMar 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark D. McDadeDirector
- W. Michael Kavanaugh, M.D.Executive Officer
- Brian G AtwoodDirector
- R. Lee DouglasDirector
- Fred E. Cohen, M.D., D.Phil.Director
- Franklin M. Berger, CFADirector
- Julie Hambleton, M.D.Executive Officer
- Francis W. SarenaExecutive Officer
- Lewis T. WilliamsExecutive Officer, Director
- Peder K. Jensen, M.D.Director
- Aron M. KnickerbockerExecutive Officer, Director
- Marc L. BelskyExecutive Officer
- Offering amount
- $21M
- Amount sold
- $21M
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Five Prime Therapeutics do?
- Five Prime Therapeutics was a clinical-stage biotech in South San Francisco developing protein- and antibody-based immuno-oncology therapies, including the FGFR2b-targeting antibody bemarituzumab for gastric cancer.
- Who founded Five Prime Therapeutics?
- Five Prime Therapeutics was founded by Lewis T. Williams.
- Who are Five Prime Therapeutics's investors?
- Five Prime Therapeutics's investors include DBL Partners, Lightstone Ventures.
- How much funding has Five Prime Therapeutics raised?
- Five Prime Therapeutics has disclosed $21M raised across 1 round.
- Who acquired Five Prime Therapeutics?
- Five Prime Therapeutics was acquired by Amgen.
- Where is Five Prime Therapeutics headquartered?
- Five Prime Therapeutics is headquartered in South San Francisco, US.